CAR T-cells have the potential to revolutionize tthe reatment of multiple hematological malignancies; however, they do not come without setbacks, as William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, explains. Therapies must be individually cultivated, which is time consuming and therefore dangerous in an aggressive disease, and the toxicities associated with CAR T-cells are considerable. Prof. Wierda discusses an alternative: CAR NK-cells. CAR NK-cell therapy appears, from early clinical trial data, to be highly effective and importantly, more tolerable than CAR T-cell therapy. This video was recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX.